Denosumab-Induced Hypocalcemia after Billroth II Gastric Bypass Surgery
Hypocalcemia is a known risk following bariatric surgery and can contribute to the development of osteoporosis. Osteoporosis is commonly treated with denosumab, though denosumab can exacerbate underlying abnormalities in calcium homeostasis. We present the case of a 59-year-old female with severe hy...
Main Authors: | Abigail M. Schmucker, Dina E. Green, Philip M. Montemuro |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Case Reports in Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2020/8833723 |
Similar Items
-
Gastric cancer surgery: Billroth I or Billroth II for distal gastrectomy?
by: Zhu Zheng-Gang, et al.
Published: (2009-12-01) -
Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer
by: Mohammed Muqeet Adnan, et al.
Published: (2014-01-01) -
Late Onset Remnant Gastric Cancer with Afferent Loop Syndrome 47 Years after Billroth II Surgery
by: Memduh şahin, et al.
Published: (2015-01-01) -
Severe, Prolonged, Denosumab-Induced Hypocalcemia With Recovery After 111 Days Of High-Dose Calcium Supplementation
by: Rachael V. McCaleb, PharmD, BCPS, et al.
Published: (2019-01-01) -
High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
by: Ishikawa K, et al.
Published: (2016-12-01)